Every Solo Song by a BTS Member to Chart on the Billboard Hot 100
BTS is one of the most successful acts in Billboard chart history.
More from Billboard
Sabrina Carpenter Fills Out BST Hyde Park Lineup With Clairo, Beabadoobee, Olivia Dean, Sola and More
Charli xcx Re-Watched All the 'Final Destination' Movies and Has Her Own Idea For One: 'Just Hot People Getting Killed'
Benson Boone Announces Fall 2025 U.K. and Ireland Arena Tour Dates
Dating to the South Korean septet's first appearance on the Billboard Hot 100 in 2017 with 'DNA,' the group has charted more than two dozen songs. Of those, 10 have reached the top 10 and six have gone all the way to No. 1: 'Dynamite' (three weeks at the summit in 2020); 'Savage Love (Laxed – Siren Beat)' with Jawsh 685 and Jason Derulo (one week, 2020); 'Life Goes On' (one week, 2020); 'Butter' (10 weeks, 2021); 'Permission to Dance' (one week, 2021); and 'My Universe' with Coldplay (one week, 2021).
Outside the group, all seven BTS members have embarked on solo careers – and scored solo Hot 100 hits. Two — Jimin and Jung Kook — have even achieved solo No. 1s, with 'Like Crazy' and 'Seven' (featuring Latto), respectively.
J-Hope became the first BTS member to notch a solo Hot 100 entry when 'Chicken Noodle Soup' featuring Becky G debuted and peaked at No. 81 in October 2019. SUGA was next (under his Agust D moniker) with 'Daechwita' in 2020, followed by V ('Christmas Tree,' January 2022), Jung Kook ('Stay Alive,' February 2022), JIN ('The Astronaut,' November 2022), RM ('Wild Flower' with Youjeen, December 2022) and Jimin ('Vibe' with TAEYANG, January 2023).
As each member extends BTS' imprint with subsequent solo songs, here's a look at all seven members' solo histories on the Hot 100 (along with a look at all of BTS' entries), each listed chronologically as of the chart dated May 31, 2025.
Song Title, Peak Position, Peak Date'Chicken Noodle Soup,' featuring Becky G, No. 81 peak, Oct. 12, 2019'More,' No. 82, July 16, 2022'Arson,' No. 96, July 30, 2022'On the Street,' with J. Cole, No. 60, March 18, 2023'LV Bag,' with Don Toliver, Pharrell Williams & Speedy, No. 83, March 8, 2025'Sweet Dreams' featuring Miguel, No. 66, March 22, 2025'Mona Lisa,' No. 65, April 5, 2025'Daechwita' (as Agust D), No. 76, June 6, 2020'Girl of My Dreams,' with Juice WRLD, No. 29, Dec. 25, 2021'That That' (PSY featuring Suga), No. 80, May 14, 2022'Haegeum' (as Agust D), No. 58, May 6, 2023'Christmas Tree,' No. 79, Jan. 8, 2022'Love Me Again,' No. 96, Aug. 26, 2023'Slow Dancing,' No. 51, Sept. 23, 2023'FRI(END)S,' No. 65, March 30, 2024'Winter Ahead' with Park Hyo Shin, No. 99, Dec. 14, 2024'White Christmas' with Bing Crosby, No. 93, Dec. 21, 2024'Stay Alive,' No. 95, Feb. 26, 2022'Left and Right' (Charlie Puth featuring Jung Kook), No. 22, July 9, 2022'Seven,' featuring Latto, No. 1 (for one week), July 29, 2023'3D,' with Jack Harlow, No. 5, Oct. 14, 2023'Too Much,' with The Kid LAROI & Central Cee, No. 44, Nov. 4, 2023'Standing Next to You,' No. 5, Nov. 18, 2023'Never Let Go,' No. 97, June 22, 2024'The Astronaut,' No. 51, Nov. 12, 2022'Running Wild,' No. 53, Nov. 30, 2024'Don't Say You Love Me,' No. 90, 2025'Wild Flower,' with Youjeen, No. 83, Dec. 17, 2022'Neva Play,' with Megan Thee Stallion, No. 36, Sept. 21, 2024
'Vibe' (Taeyang featuring Jimin), No. 76, Jan. 28, 2023'Set Me Free, Pt. 2,' No. 30, April 1, 2023'Like Crazy,' No. 1 (for one week), April 8, 2023'Angel, Pt. 1,' with Kodak Black, NLE Choppa, JVKE & Muni Long, No. 65, June 3, 2023'Smeraldo Garden Marching Band,' with Loco, No. 88, July 13, 2024'Who,' No. 12, Aug. 10, 2024'DNA,' No. 67, Oct. 14, 2017'Mic Drop,' featuring Desiigner, No. 28, Dec. 16, 2017'Fake Love,' No. 10, June 2, 2018'Idol,' featuring Nicki Minaj, No. 11, Sept. 8, 2018'Waste It on Me' (Steve Aoki featuring BTS), No. 89, Nov. 10, 2018'Make It Right,' featuring Lauv, No. 76, Nov. 2, 2019'Boy With Luv,' featuring Halsey, No. 8, April 27, 2019'Black Swan,' No. 57, Feb. 1, 2020'On,' No. 4, March 7, 2020'Filter,' No. 87, March 7, 2020'My Time,' No. 84, March 7, 2020'Dynamite,' No. 1, Sept. 5, 2020'Savage Love (Laxed – Siren Beat),' with Jawsh 685 & Jason Derulo, No. 1, Oct. 17, 2020'Life Goes On,' No. 1, Dec. 5, 2020'Fly to My Room,' No. 69, Dec. 5, 2020'Blue & Grey,' No. 13, Dec. 5, 2020'Telepathy,' No. 70, Dec. 5, 2020'Dis-ease,' No. 72, Dec. 5, 2020'Stay,' No. 22, Dec. 5, 2020'Film Out,' No. 81, April 17, 2021'Butter,' No. 1, June 5, 2021'Permission To Dance,' No. 1, July 25, 2021'My Universe,' with Coldplay, No. 1, Oct. 9, 2021'Yet To Come,' No. 13, June 25, 2022'Run BTS,' No. 73, June 25, 2022'Bad Decisions,' with Benny Blanco & Snoop Dogg, No. 10, Aug. 20, 2022'Take Two,' No. 48, June 24, 2023
Best of Billboard
Chart Rewind: In 1989, New Kids on the Block Were 'Hangin' Tough' at No. 1
Four Decades of 'Madonna': A Look Back at the Queen of Pop's Debut Album on the Charts
Chart Rewind: In 1990, Madonna Was in 'Vogue' Atop the Hot 100
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
Water Tower Research Highlights Ainos' AI Nose Accuracy Breakthrough in Elderly Care Monitoring: SmellTech Gets Smarter
PRESS RELEASE: Paid Content from ACCESS Newswire. The AP news staff was not involved in its creation. AI Nose accuracy in elderly care improved to 85% with additional Smell ID training AI-friendly healthcare policies to provide tailwinds for commercial rollout SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 3, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ... Published [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] AI Nose accuracy in elderly care improved to 85% with additional Smell ID training AI-friendly healthcare policies to provide tailwinds for commercial rollout SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 3, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ('Ainos' or the 'Company'), a leader in AI-powered scent digitization, today announced that Water Tower Research ('WTR') has published a report highlighting a significant milestone in the Company's AI Nose project for elderly care. AI Nose has reached approximately 85% accuracy in excretion odor detection-improving over the recently met internal milestone of 80%. Key Highlights from the Report: AI Nose Accuracy enhanced through machine learning at scale: The improved accuracy is based on 254 subject events and 2,119 sample entries in Japan and Taiwan. WTR estimates AI Nose achieved ~92% sensitivity, supporting the platform's reliability for real-time hygiene monitoring in long-term care environments. Data-driven machine learning and AI model training contribute to the improved accuracy, underscoring AI Nose's ability to enhance detection with increased data input. Addressing aging population challenges in Japan and Taiwan: AI Nose offers a timely and scalable solution to the rising demand for senior care driven by the aging populations of Japan and Taiwan. In Japan, nearly 30% of the population is aged 65 or older, a figure projected to rise to 35% by 2040-creating an anticipated shortfall of ~570,000 caregivers. In Taiwan, the elderly population is expected to exceed 20% by 2025, with one of the world's lowest birthrates. AI-integrated healthcare policy tailwinds support AI Nose adoption: AI Nose is strategically aligned with major AI-friendly healthcare digital transformation initiatives, including Japan's Society 5.0 and HealthcareDX frameworks and Taiwan's long-term care programs. These policy tailwinds are expected to accelerate commercialization pathways and generate scalable demand for AI Nose in high-need healthcare settings. Commercial rollout targeted for 2026, with scalable Asia-Pacific growth potential: Ainos is advancing toward commercial deployment of AI Nose in long-term care facilities in 2026, following pilot testing through the second half of 2025. This timeline positions Ainos to capture early-mover advantage in Japan's aging population segment, with expansion opportunities in other Asian regions, reflecting AI Nose's scalability and regional relevance in addressing healthcare labor shortages and chronic care demands. Pioneering SmellTech in $29.8-billion E-nose market: Ainos is positioning AI Nose as a category-defining SmellTech platform at the leading edge of the $29.8 billion global electronic nose market in 2025. By combining proprietary AI models with advanced gas sensor arrays, AI Nose is designed to unlock new, data-driven applications across healthcare, industrial, and robotics sectors. This differentiated approach positions Ainos as a potential first mover in digitized scent detection, with scalable upside across high-growth verticals. Read the Full Water Tower Research Report Here: About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name 'Ainos' combines 'AI' and 'Nose' to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit . Follow Ainos on X, formerly known as Twitter, ( @AinosInc ) and LinkedIn to stay up-to-date. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contact Information Feifei Shen [email protected] SOURCE: Ainos, Inc. press release
Yahoo
2 hours ago
- Yahoo
Asia-Pacific HVAC Market Forecast 2025-2034: Trends and Shares by Equipment, Implementation Type, End Use and Country
Urbanization, energy-efficient demand, and construction sector expansion primarily driving growth Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific HVAC Market Report and Forecast 2025-2034" has been added to offering. According to recent findings, the Asia-Pacific HVAC market size is poised to expand at a CAGR of 7.2% between 2025 and 2034. This growth is largely fueled by the rising demand for energy-efficient systems and the proliferation of construction activities. As populations increase and urban spaces expand, countries like China, India, Japan, and other Southeast Asian nations are driving significant adoption of HVAC solutions. The intensified push for eco-friendly systems is a response to the growing awareness around energy efficiency and reduced greenhouse gas emissions. Rapid construction in emerging economies has also stimulated HVAC demand. From office structures and shopping complexes to healthcare facilities, the need for advanced climate control solutions is escalating. As disposable incomes rise and living standards improve, there is an increasing preference for modern HVAC systems in households. Technological advancements are steadily reshaping the HVAC landscape in Asia-Pacific. Smart controls, IoT solutions, and AI integration are revolutionizing system efficiency, offering enhanced remote monitoring, and predictive maintenance capabilities. These innovations not only improve user convenience but also minimize operational costs and environmental effects. Environmental regulations and policies are pivotal in this market's evolution, promoting the development of sustainable HVAC products. The focus on green building certifications and energy efficiency standards has led to increased investments in R&D, enabling the creation of products that adhere to strict environmental guidelines. This shift is stimulating market growth while supporting the construction sector's expansion. Additionally, industrial sectors such as manufacturing plants, data centers, and logistics require precise climate control to protect equipment and enhance performance. This necessity further drives the demand for sophisticated HVAC solutions. The attractiveness of the Asia-Pacific HVAC market is further amplified by the growing prevalence of smart homes and building automation systems. Integration of HVAC solutions with smart technology allows for seamless energy management and user-friendly interfaces, fostering a continued interest in connected, efficient systems for both residential and commercial applications. Furthermore, there is a burgeoning trend in retrofitting older buildings with state-of-the-art HVAC systems, contributing notably to market revenues. Countries like Japan and Australia, characterized by stringent energy standards, are leading this initiative, reflecting a commitment to sustainability by updating existing infrastructure for improved energy efficiency. Market Segmentation By Equipment: Heating, Heat Pumps, Furnaces, Unitary Heaters, Ventilation, Air-Handling Units, Air Filters and Purifiers, Ventilation Fans, Dehumidifiers and Humidifiers, Cooling, Unitary Air Conditioners, VRF Systems, Chillers, Coolers, Cooling Towers, Others. By Implementation Type: New Constructions, Retrofits. By End Use: Residential, Commercial, Industrial. By Country: China, Japan, India, ASEAN, Australia, Others. Competitive Landscape The report reviews market shares, plant turnarounds, capacities, investments, and mergers and acquisitions among leading companies in the Asia-Pacific HVAC sector. Key players include: LG Corp. Robert Bosch GmbH Hitachi Ltd. Samsung Electronics Co. Ltd. Haier Smart Home Co. Ltd. Mitsubishi Electric Corporation Panasonic Holdings Corp. Daikin Industries Ltd. Lennox International Inc. Carrier Global Corp. Danfoss A/S Others For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
2 hours ago
- Yahoo
Asia-Pacific Pediatric Interventional Cardiology Industry Report 2025-2033: Insights Into Markets, Shares, Companies, Trends, Growth Opportunities and More
Driving factors include rising congenital heart defect cases, healthcare advancements, governmental support, and demographic trends in China and India Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Pediatric Interventional Cardiology Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to offering. The Asia-Pacific Pediatric Interventional Cardiology Market is expected to reach US$ 1.52 billion by 2033 from US$ 829.09 million in 2024, with a CAGR of 7.01% from 2025 to 2033. Increased cases of congenital heart defects, improved healthcare infrastructure, increased public awareness, technological innovations, encouraging governmental support, and increasing child populations - especially in developing countries such as China and India - are all contributing to the Asia-Pacific pediatric interventional cardiology market. The specialty branch of pediatric interventional cardiology is committed to minimally invasive diagnosis and treatment of cardiac ailments in neonates, children, and adolescents. Interventional cardiologists perform procedures such as fixing congenital heart defects, opening narrowed valves or arteries, and closing septal defects with catheters inserted via blood vessels instead of open heart surgery. Typically, imaging devices such as echocardiography or fluoroscopy guide these operations. In comparison to surgery, the technique offers faster recovery, less time in the hospital, and fewer complications. To address congenital and acquired cardiac issues and improve the quality of life of young children, pediatric interventional cardiology is a must. Several key drivers are responsible for the significant growth of the Asia-Pacific pediatric interventional cardiology market. The demand for better pediatric cardiac care is fueled by the increasing prevalence of congenital heart diseases, particularly in populous countries such as China and India. Availability of minimally invasive interventions is being enhanced by improved healthcare infrastructure, increased government support, and increased investment in medical technology. In addition, the availability of skilled healthcare professionals, increased health insurance coverage, and improved parental awareness are all contributing to market growth. Adoption of pediatric interventional cardiology in the Asia-Pacific region is being led by advances in diagnostic equipment and interventional devices, which also facilitate enhanced outcomes. The Asia-Pacific Pediatric Interventional Cardiology Market is expected to grow enormously because of the rise in the number of congenital heart abnormalities (CHDs). The rate of babies born with congenital heart defects has increased enormously because of the rise in birth rates in countries like China and India. Due to advances in diagnostic technologies such as newborn screening and fetal echocardiography, early identification has increased. As parents and physicians become increasingly aware, more children are being diagnosed early and referred for treatment. Open cardiac surgery is less required when these issues are treated with minimally invasive methods offered by pediatric interventional cardiology. Advanced pediatric cardiac interventions remain in high demand in the Asia-Pacific region because of the increasing incidence of congenital heart disease and greater access to specialist care. The Asia-Pacific Pediatric Interventional Cardiology Market is likely to grow tremendously with the enhanced healthcare infrastructure. In countries such as China, India, and Southeast Asia, economic growth and urbanization have led to massive investments in healthcare systems. Availability of quality interventional therapy to children with heart issues has been enhanced through the expansion of specialist cardiac centers, the presence of state-of-the-art medical technology, and improved training of pediatric cardiologists. Treatment outcomes and hospital capacities are being enhanced through international cooperation and public-private alliances. Demand is also being driven by the expansion of digital health platforms and telemedicine, which are bridging the gap between rural communities and specialist cardiac care. In Asia-Pacific, increasing numbers of children are enjoying early diagnosis and minimally invasive cardiac surgery as healthcare systems improve. Asia-Pacific Pediatric Interventional Cardiology Market is anticipated to grow enormously due to technological advances in minimally invasive technology. Pediatric cardiac therapy has been revolutionized by leaps in imaging modalities, catheter-based intervention, and downsized devices. Congenital heart disease now can be targeted exactly and effectively with no need for open-heart surgery due to these technologies that reduce hospital stay, accelerate recovery, and reduce risk of complications. The development of smaller, child-specific devices such as balloons, stents, and occluders has enhanced the safety and effectiveness of newborn and young children's treatments. With growing investments in healthcare innovation, countries in the Asia-Pacific region are adopting these advanced tools at a growing pace. Treatment options and market expansion are being significantly enhanced by the incorporation of technology in pediatric cardiology as it becomes increasingly accessible and affordable. One major obstacle facing the Asia-Pacific pediatric interventional cardiology market is the high cost of therapy. Many families, especially those in lower-income areas, cannot afford the high costs of advanced operations, specialist equipment, and hospital stays. Even though insurance coverage is growing, it frequently falls short of covering all expenses, particularly in developing nations. The overall development and efficacy of pediatric interventional cardiology in the area are hampered by this financial barrier, which restricts children with congenital heart abnormalities' access to prompt, life-saving therapies. The Asia-Pacific Pediatric Interventional Cardiology Market faces many challenges, one of which is limited access to specialized care. Advanced pediatric cardiac centers are few and far between, and healthcare infrastructure is sometimes inadequate in rural and isolated places. Timely identification and treatment of congenital cardiac abnormalities are hindered by this lack of access. Long commutes to receive care may be necessary for families in underprivileged areas, further postponing intervention. This discrepancy in access to healthcare poses serious obstacles to fair treatment throughout the area. Key Attributes Report Attribute Details No. of Pages 200 Forecast Period 2024-2033 Estimated Market Value (USD) in 2024 $829.09 Million Forecasted Market Value (USD) by 2033 $1.52 Billion Compound Annual Growth Rate 7% Regions Covered Asia-Pacific Key Topics Covered1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Asia-Pacific Pediatric Interventional Cardiology Market5.1 Historical Market Trends5.2 Market Forecast6. Asia-Pacific Pediatric Interventional Cardiology Market Share Analysis6.1 By Device Type6.2 By Procedure6.3 By End Use6.4 By Countries7. Device Type7.1 Transcatheter Heart Valves7.2 Atherectomy Devices7.3 Catheters7.4 Closure Devices7.5 Balloons7.6 Stents7.7 Others8. Procedure8.1 Catheter-based Valve Implantation8.2 Congenital Haert Defect Correction8.3 Angioplasty8.4 Coronary Thrombectomy8.5 Others9. End Use9.1 Hospitals9.2 Ambulatory Surgical Centers9.3 Others10. Countries10.1 China10.2 Japan10.3 India10.4 South Korea10.5 Thailand10.6 Malaysia10.7 Indonesia10.8 Australia10.9 New Zealand10.10 Rest of Asia-Pacific11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis13.1 Abbott Laboratories Inc.13.1.1 Overviews13.1.2 Key Person13.1.3 Recent Developments & Strategies13.1.4 Revenue Analysis13.2 Boston Scientific Corporation13.3 Medtronic PLC13.4 B. Braun13.5 Biosensors International Group, Ltd.13.6 Siemens AG13.7 Cardinal Health Inc.13.8 Terumo Medical CorporationFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
